[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MiNK Therapeutics director Peter Behner received 1,173 restricted stock units (RSUs) on 09/02/2025, granted in lieu of cash board and committee retainers. Each RSU represents a contingent right to one share of common stock and will vest one month from the grant date.

After the grant, Mr. Behner beneficially owns 18,649 shares of MiNK common stock on a direct basis. The reported per-share value associated with the grant is $13.86. The Form 4 was submitted to disclose this change in beneficial ownership.

Insights

Corporate Governance Expert

TL;DR: Routine director compensation in equity form aligns interests but is generally immaterial to valuation unless grants are large.

The grant of 1,173 RSUs to a director as compensation replaces cash retainers with equity, which commonly serves to align a board member's incentives with shareholders. The RSUs vest quickly—one month from grant—so the award converts to shares on a short timeline. This is a standard governance practice; there is no disclosure of any accelerated vesting conditions or performance-based features beyond the one-month vesting note.

Securities Analyst

TL;DR: Transaction is a routine insider grant and likely has neutral immediate market impact given its size relative to outstanding shares.

The Form 4 reports a non-derivative acquisition of 1,173 RSUs at an indicated value of $13.86 per share and a resulting direct beneficial ownership of 18,649 shares. This is a disclosure of insider compensation rather than a market purchase or sale. Absent further context on total share count or subsequent sales, the item is informational and not a material corporate event by itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behner Peter

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		1,173	A	$13.86(1)	18,649	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MiNK Therapeutics (INKT) report?

The Form 4 reports that director Peter Behner was granted 1,173 RSUs on 09/02/2025, received in lieu of cash retainers.

How many shares does Peter Behner own after the reported transaction?

Following the reported transaction, Peter Behner beneficially owns 18,649 shares of MiNK Therapeutics common stock on a direct basis.

When do the RSUs granted to the director vest?

The RSUs will vest one month from the grant date, after which each RSU represents a right to one share of common stock.

What value was reported for the RSU grant on the Form 4?

The Form 4 shows an indicative per-share amount of $13.86 associated with the reported RSU grant.

Was the RSU grant reported as a purchase, sale, or other type of transaction?

The RSU grant is reported as an acquisition (A) of non-derivative securities, reflecting issuance of equity-based compensation.